Abstract
Antagonists of AT1 receptor are interesting substances to develop drugs that can be used for the treatment of hypertension and other diseases that affect the cardiovascular system. This study investigates the main interactions between various AT1 antagonists and the biological target by applying fragment-based drug design (Hologram QSAR - HQSAR). The proposed HQSAR model yielded significant correlation coefficients (q2 = 0.764 and r2 = 0.914), indicating that the method is rigorous and reliable. All models were externally validated using a test set and the results showed good agreement between the experimental and predicted data (r2 test = 0.740). Therefore, our model can positively contribute to understand the structural features involved in the main interactions between the AT1 antagonists and the residues of the binding site.
Keywords: Angiotensin II, drug design, fragment-based method, hypertension, molecular modeling.
Protein & Peptide Letters
Title:Identifying Structural Features Related to the Biological Activity of a Series of AT1 Antagonists from Fragment-based Drug Design
Volume: 21 Issue: 6
Author(s): Danielle da C. Silva, Vinícius G. Maltarollo and Kathia M. Honorio
Affiliation:
Keywords: Angiotensin II, drug design, fragment-based method, hypertension, molecular modeling.
Abstract: Antagonists of AT1 receptor are interesting substances to develop drugs that can be used for the treatment of hypertension and other diseases that affect the cardiovascular system. This study investigates the main interactions between various AT1 antagonists and the biological target by applying fragment-based drug design (Hologram QSAR - HQSAR). The proposed HQSAR model yielded significant correlation coefficients (q2 = 0.764 and r2 = 0.914), indicating that the method is rigorous and reliable. All models were externally validated using a test set and the results showed good agreement between the experimental and predicted data (r2 test = 0.740). Therefore, our model can positively contribute to understand the structural features involved in the main interactions between the AT1 antagonists and the residues of the binding site.
Export Options
About this article
Cite this article as:
Silva da C. Danielle, Maltarollo G. Vinícius and Honorio M. Kathia, Identifying Structural Features Related to the Biological Activity of a Series of AT1 Antagonists from Fragment-based Drug Design, Protein & Peptide Letters 2014; 21 (6) . https://dx.doi.org/10.2174/092986652106140425122007
DOI https://dx.doi.org/10.2174/092986652106140425122007 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Patents in Diagnosis and Treatment for Inborn Errors of Metabolism
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Possible Involvement of TRP Channels in Cardiac Hypertrophy and Arrhythmia
Current Topics in Medicinal Chemistry Editorial [Hot topic: Current Topics on Hypolipidaemic Therapy and Cardiovascular Risk Assessment (Guest Editors: Evangelos C. Rizos and Moses S. Elisaf)]
Current Vascular Pharmacology Novel Concepts in the Pathogenesis and Management of Pediatric Hypertension
Current Pediatric Reviews Genetics of Cholesterol and Lipoprotein Metabolism
Recent Patents on Cardiovascular Drug Discovery Could Better Phenotyping Small Vessel Disease Provide New Insights into Alzheimer Disease and Improve Clinical Trial Outcomes?
Current Alzheimer Research Green Tea Polyphenols as an Anti-Oxidant and Anti-Inflammatory Agent for Cardiovascular Protection
Cardiovascular & Hematological Disorders-Drug Targets Healing the Diabetic Heart: Modulation of Cardiometabolic Syndrome through Peroxisome Proliferator Activated Receptors (PPARs)
Current Molecular Pharmacology Mesenchymal Stem Cell Therapy for Patients with Ischemic Heart Failure- Past, Present, and Future
Current Stem Cell Research & Therapy Pre-Emptive Conditioning of the Ischemic Heart
Cardiovascular & Hematological Agents in Medicinal Chemistry Inhibition of sPLA2-IIA, C-reactive Protein or Complement: New Therapy for Patients with Acute Myocardial Infarction?
Cardiovascular & Hematological Disorders-Drug Targets Access to Medicines and the Safety of the People
Reviews on Recent Clinical Trials Perioperative Safety of Warfarin Therapy and Reversal
Current Drug Safety Update on Medical and Surgical Management of Intracerebral Hemorrhage
Reviews on Recent Clinical Trials Pulmonary Arterial Hypertension in HIV-infected Patients
Current Hypertension Reviews Emerging Strategies and Challenges for Controlled Delivery of Taxanes: A Comprehensive Review
Current Drug Metabolism Processed Foods, Dysbiosis, Systemic Inflammation, and Poor Health
Current Nutrition & Food Science Heart Failure Epidemiology: European Perspective
Current Cardiology Reviews Editorial: (New Drug (LCZ696) for the Treatment of Heart Failure with Reduced Ejection Fraction After 10 Years. Can One Study Change the Guidelines?)
Current Vascular Pharmacology Editorial [ Hot Topic: Antidepressant Drug Design (Executive Editor: Lee E. Schechter)]
Current Pharmaceutical Design